Age-related macular degeneration (AMD) is the leading cause of vision loss in the Western world,
1 leading to poor quality of life outcomes especially for reading, driving, and looking after oneself.
2–4 Recent advances in managing early stages of AMD
5 and treatments for end stage geographic atrophy are currently being explored (ARVO abstract: 2019, 4983). Previous studies have investigated impaired visual acuity (VA),
6 dark adaptation,
7 flicker thresholds,
8 photostress recovery time,
9 and microperimetry in AMD.
10 Traditionally, high-contrast visual acuity (HCVA) has been used as a functional end point for clinical studies and for monitoring changes in function but is considered a poor measure of early stages of functional impairment due to the limited area of retinal function assessed, and reductions in other forms of macular function preceding changes in HCVA.
11,12 That being said, photopic vanishing optotypes may be more effective in AMD.
13 Visual acuity has also been shown to be poor in identifying ocular pathologies, such as glaucoma
14 and diabetic retinopathy.
15 Disagreement also exists in the spatial correlation between sensitivity loss, as measured by microperimetry, and morphological changes in the retina.
16,17 For instance, retinal sensitivity loss in eyes with good VA, has been demonstrated in regions with soft drusen and retinal pigmented epithelial change.
18 Regulatory agencies are recognizing the need for a more robust measure of functional change than best corrected visual acuity (BCVA) as a functional end point for retinal disease and the need for novel functional end points to be developed.
19